Based on the Celularity Inc stock forecast from 0 analysts, the average analyst target price for Celularity Inc is not available over the next 12 months. Celularity Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Celularity Inc is Bearish, which is based on 1 positive signals and 8 negative signals. At the last closing, Celularity Inc’s stock price was USD 2.30. Celularity Inc’s stock price has changed by -17.41% over the past week, -20.28% over the past month and +923.17% over the last year.
No recent analyst target price found for Celularity Inc
No recent average analyst rating found for Celularity Inc
Company Overview Celularity Inc
Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. The company operates through Cell Therapy, Degenerative Disease, and BioBanking segments. Its lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease. In addition, the company is developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. Celularity Inc. produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. Celularity Inc. was founded in 1998 and is based in Florham Park, New Jersey. Read Less
Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. The company operates through Cell Therapy, Degenerative Disease, and BioBanking segments. Its ...Read More
Frequently Asked Questions About Celularity Inc (CELU) Stock
Stock Target Advisor's fundamental analysis for Celularity Inc's stock is Bearish.
Unfortunately we do not have enough data on CELU's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on CELU's stock to indicate what its average analyst target is.
CELU stock's Price/Earning ratio is 2.15.
Our analysis grades CELU stock's Price / Earning ratio at D-. This means that CELU stock's Price/Earning ratio is above 39% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this CELU may be fairly valued for its sector
The last closing price of CELU's stock was USD 2.30.
The most recent market capitalization for CELU is USD 0.06B.
Unfortunately we do not have enough analyst data on CELU's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Celularity Inc's stock.
As per our most recent records Celularity Inc has 120 Employees.
Celularity Inc's registered address is 170 Park Avenue, Florham Park, NJ, United States, 07932.
You can get more information about it from Celularity Inc's website at https://www.celularity.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Celularity Inc (CELU) Stock
Stock Target Advisor's fundamental analysis for Celularity Inc's stock is Bearish.
Unfortunately we do not have enough data on CELU's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on CELU's stock to indicate what its average analyst target is.
CELU stock's Price/Earning ratio is 2.15.
Our analysis grades CELU stock's Price / Earning ratio at D-. This means that CELU stock's Price/Earning ratio is above 39% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this CELU may be fairly valued for its sector
The last closing price of CELU's stock was USD 2.30.
The most recent market capitalization for CELU is USD 0.06B.
Unfortunately we do not have enough analyst data on CELU's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Celularity Inc's stock.
As per our most recent records Celularity Inc has 120 Employees.
Celularity Inc's registered address is 170 Park Avenue, Florham Park, NJ, United States, 07932.
You can get more information about it from Celularity Inc's website at https://www.celularity.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for CELU !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
